JMIR Publications

ABSTRACT

Japan's aging society concentrates pneumonia burden across communities, long‑term care, perioperative pathways, and hospitals. Adult pneumococcal and influenza vaccination are supported by trials and meta‑analyses and often cost‑effective, yet realized value depends on targeting, measurement, financing, and pairing with bedside prevention such as oral care and hospital‑acquired pneumonia bundles. This Viewpoint proposes a formative, indicator‑driven architecture linking cost‑effectiveness to operations by aligning vaccination with complementary oral‑care prevention and value‑based payment under existing policy infrastructure. Working within the Ministry of Health, Labour and Welfare/Central Social Insurance Medical Council health technology assessment framework, C2H methods, and claims–electronic health record linkage via My Number insurance card, we specify a compact national indicator set: vaccination coverage and timeliness, non‑ventilator hospital‑acquired pneumonia, ventilator‑associated pneumonia, postoperative and stroke‑associated pneumonia, antibiotic days of therapy, and length of stay, with pragmatic risk adjustment and present‑on‑admission flags. Value levers first reward reliable reporting and adherence to evidence‑based bundles, then share verified, risk‑adjusted savings. Long‑term care facilities receive add‑ons for professional oral care in high‑risk residents; hospitals receive quality add‑ons and shared savings; perioperative pathways require oral management; stroke units standardize oral hygiene with dysphagia screening. A phased roadmap details pilot co‑design, governance, risk‑adjusted reporting with equity safeguards, and iterative recalibration using real‑world evidence. The learning loop—measure, report, improve, generate evidence, adapt cost‑effectiveness, recalibrate payment—converts modeled value into lived experience: fewer pneumonias, reduced antibiotic exposure, shorter stays, improved function and dignity at acceptable or lower costs.